Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.

PepCan - University of Arkansas for Medical Sciences

HPV-T - BGI Group

https://meetings.asco.org/abstracts-presentations/239560/

Mayumi Nakagawa; Teresa Evans; Milan Bimali; Hannah Coleman; Jasmine Crane; Nadia Darwish; Yong-Chen Lu; Intawat Nookaew; Keanna Marsh; Michael Scott Robeson; Takeo Shibata; David Ussery; William Greenfield

Apr 25, 2024